報價延遲最少15分鐘:2025/06/03 23:23 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.22 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.17/-0.26
|
|
企業價值
669.65M
|
| 資產負債 |
|
每股賬面淨值
2.09
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
259.19M
|
|
每股收益
3.78
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 23:23 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |